Joseph Chen, Ana Ruiz-Garcia, Leonard P James, Gerson Peltz, Holger Thurm, Jill Clancy, Jennifer Hibma. Clin Pharmacol Ther 2021
Times Cited: 6
Times Cited: 6
Times Cited
Times Co-cited
Similarity
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Alice T Shaw, Enriqueta Felip, Todd M Bauer, Benjamin Besse, Alejandro Navarro, Sophie Postel-Vinay, Justin F Gainor, Melissa Johnson, Jorg Dietrich, Leonard P James,[...]. Lancet Oncol 2017
Alice T Shaw, Enriqueta Felip, Todd M Bauer, Benjamin Besse, Alejandro Navarro, Sophie Postel-Vinay, Justin F Gainor, Melissa Johnson, Jorg Dietrich, Leonard P James,[...]. Lancet Oncol 2017
66
Lorlatinib Should Not be Considered as the Preferred First-Line Option in Patients With Advanced ALK Rearranged NSCLC.
David Ross Camidge. J Thorac Oncol 2021
David Ross Camidge. J Thorac Oncol 2021
50
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Benjamin J Solomon, Benjamin Besse, Todd M Bauer, Enriqueta Felip, Ross A Soo, D Ross Camidge, Rita Chiari, Alessandra Bearz, Chia-Chi Lin, Shirish M Gadgeel,[...]. Lancet Oncol 2018
Benjamin J Solomon, Benjamin Besse, Todd M Bauer, Enriqueta Felip, Ross A Soo, D Ross Camidge, Rita Chiari, Alessandra Bearz, Chia-Chi Lin, Shirish M Gadgeel,[...]. Lancet Oncol 2018
50
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
Alice T Shaw, Todd M Bauer, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, Geoffrey Liu, Julien Mazieres, Dong-Wan Kim, Tony Mok, Anna Polli,[...]. N Engl J Med 2020
Alice T Shaw, Todd M Bauer, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, Geoffrey Liu, Julien Mazieres, Dong-Wan Kim, Tony Mok, Anna Polli,[...]. N Engl J Med 2020
33
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Solange Peters, D Ross Camidge, Alice T Shaw, Shirish Gadgeel, Jin S Ahn, Dong-Wan Kim, Sai-Hong I Ou, Maurice Pérol, Rafal Dziadziuszko, Rafael Rosell,[...]. N Engl J Med 2017
Solange Peters, D Ross Camidge, Alice T Shaw, Shirish Gadgeel, Jin S Ahn, Dong-Wan Kim, Sai-Hong I Ou, Maurice Pérol, Rafal Dziadziuszko, Rafael Rosell,[...]. N Engl J Med 2017
33
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James Chih-Hsin Yang, Ji-Youn Han, Jong-Seok Lee, Maximilian J Hochmair, Jacky Yu-Chung Li, Gee-Chen Chang, Ki Hyeong Lee,[...]. N Engl J Med 2018
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James Chih-Hsin Yang, Ji-Youn Han, Jong-Seok Lee, Maximilian J Hochmair, Jacky Yu-Chung Li, Gee-Chen Chang, Ki Hyeong Lee,[...]. N Engl J Med 2018
33
Clinical Management of Adverse Events Associated with Lorlatinib.
Todd M Bauer, Enriqueta Felip, Benjamin J Solomon, Holger Thurm, Gerson Peltz, Marc D Chioda, Alice T Shaw. Oncologist 2019
Todd M Bauer, Enriqueta Felip, Benjamin J Solomon, Holger Thurm, Gerson Peltz, Marc D Chioda, Alice T Shaw. Oncologist 2019
33
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
Leora Horn, Ziping Wang, Gang Wu, Elena Poddubskaya, Tony Mok, Martin Reck, Heather Wakelee, Alberto A Chiappori, Dae Ho Lee, Valeriy Breder,[...]. JAMA Oncol 2021
Leora Horn, Ziping Wang, Gang Wu, Elena Poddubskaya, Tony Mok, Martin Reck, Heather Wakelee, Alberto A Chiappori, Dae Ho Lee, Valeriy Breder,[...]. JAMA Oncol 2021
33
Lorlatinib Should Be Considered as the Preferred First-Line Option in Patients With Advanced ALK-Rearranged NSCLC.
Misako Nagasaka, Sai-Hong Ignatius Ou. J Thorac Oncol 2021
Misako Nagasaka, Sai-Hong Ignatius Ou. J Thorac Oncol 2021
33
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James C H Yang, Ji-Youn Han, Maximilian J Hochmair, Ki Hyeong Lee, Angelo Delmonte, Maria Rosario García Campelo, Dong-Wan Kim,[...]. J Clin Oncol 2020
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James C H Yang, Ji-Youn Han, Maximilian J Hochmair, Ki Hyeong Lee, Angelo Delmonte, Maria Rosario García Campelo, Dong-Wan Kim,[...]. J Clin Oncol 2020
33
Population pharmacokinetic model with time-varying clearance for lorlatinib using pooled data from patients with non-small cell lung cancer and healthy participants.
Joseph Chen, Brett Houk, Yazdi K Pithavala, Ana Ruiz-Garcia. CPT Pharmacometrics Syst Pharmacol 2021
Joseph Chen, Brett Houk, Yazdi K Pithavala, Ana Ruiz-Garcia. CPT Pharmacometrics Syst Pharmacol 2021
33
An Integrated Approach for Assessing the Impact of Renal Impairment on Pharmacokinetics of Drugs in Development: Pivotal Role of PBPK Modelling.
Karen Rowland Yeo, Eva Gil Berglund. Clin Pharmacol Ther 2021
Karen Rowland Yeo, Eva Gil Berglund. Clin Pharmacol Ther 2021
100
Optimized Alectinib Dose Regimen for Treatment of Patients With ALK-Positive Non-Small Cell Lung Cancer Based on Robust Pharmacometric Analyses and Clinical Evidence.
Nicolas Frey, Walter Bordogna, Bogdana Balas, Thorsten Ruf, Venice Archer, Elena Guerini. Clin Pharmacol Ther 2021
Nicolas Frey, Walter Bordogna, Bogdana Balas, Thorsten Ruf, Venice Archer, Elena Guerini. Clin Pharmacol Ther 2021
50
The Evidence REVEAL Study: Exploring the Use of Real-World Evidence and Complex Clinical Trial Design by the European Pharmaceutical Industry.
Peter Varnai, Anoushka Davé, Kristine Farla, Anke Nooijen, Liana Petrosova. Clin Pharmacol Ther 2021
Peter Varnai, Anoushka Davé, Kristine Farla, Anke Nooijen, Liana Petrosova. Clin Pharmacol Ther 2021
20
Application of quantitative systems pharmacology to guide the optimal dosing of COVID-19 vaccines.
Mario Giorgi, Rajat Desikan, Piet H van der Graaf, Andrzej M Kierzek. CPT Pharmacometrics Syst Pharmacol 2021
Mario Giorgi, Rajat Desikan, Piet H van der Graaf, Andrzej M Kierzek. CPT Pharmacometrics Syst Pharmacol 2021
16
Response to "Optimized Alectinib Dose Regimen for Treatment of Patients With ALK-Positive NSCLC Based on Robust Pharmacometric Analyses and Clinical Evidence".
Stefanie L Groenland, Dieuwertje R Geel, Jos H Beijnen, Egbert F Smit, Alwin D R Huitema, Neeltje Steeghs. Clin Pharmacol Ther 2021
Stefanie L Groenland, Dieuwertje R Geel, Jos H Beijnen, Egbert F Smit, Alwin D R Huitema, Neeltje Steeghs. Clin Pharmacol Ther 2021
100
Population Pharmacokinetics and Pharmacodynamics of the Neutralizing Antibodies Bamlanivimab and Etesevimab in Patients With Mild to Moderate COVID-19 Infection.
Emmanuel Chigutsa, Lisa O'Brien, Lisa Ferguson-Sells, Amanda Long, Jenny Chien. Clin Pharmacol Ther 2021
Emmanuel Chigutsa, Lisa O'Brien, Lisa Ferguson-Sells, Amanda Long, Jenny Chien. Clin Pharmacol Ther 2021
16
Use of Partial Area Under the Curve in Bioavailability or Bioequivalence Assessments: A Regulatory Perspective.
Lanyan Fang, Ramana Uppoor, Mingjiang Xu, Satish Sharan, Hao Zhu, Nilufer Tampal, Bing Li, Lei Zhang, Robert Lionberger, Liang Zhao. Clin Pharmacol Ther 2021
Lanyan Fang, Ramana Uppoor, Mingjiang Xu, Satish Sharan, Hao Zhu, Nilufer Tampal, Bing Li, Lei Zhang, Robert Lionberger, Liang Zhao. Clin Pharmacol Ther 2021
100
Current and Next Steps Toward Prediction of Human Dose for Gene Therapy Using Translational Dose-Response Studies.
Sergey Aksenov, John C Roberts, Ganesh Mugundu, Karen Thudium Mueller, Indranil Bhattacharya, Michael A Tortorici. Clin Pharmacol Ther 2021
Sergey Aksenov, John C Roberts, Ganesh Mugundu, Karen Thudium Mueller, Indranil Bhattacharya, Michael A Tortorici. Clin Pharmacol Ther 2021
25
Model Informed Drug Development: Collaboration Through A Common Framework.
Richard J Anziano, Peter A Milligan. Clin Pharmacol Ther 2021
Richard J Anziano, Peter A Milligan. Clin Pharmacol Ther 2021
50
Industrial Perspective on the Benefits Realized From the FDA's Model-Informed Drug Development Paired Meeting Pilot Program.
Gerald R Galluppi, Satjit Brar, Luzelena Caro, Yuan Chen, Nicolas Frey, Hans Peter Grimm, Deanne Jackson Rudd, Chi-Chung Li, Mindy Magee, Arnab Mukherjee,[...]. Clin Pharmacol Ther 2021
Gerald R Galluppi, Satjit Brar, Luzelena Caro, Yuan Chen, Nicolas Frey, Hans Peter Grimm, Deanne Jackson Rudd, Chi-Chung Li, Mindy Magee, Arnab Mukherjee,[...]. Clin Pharmacol Ther 2021
25
A Model-Based Workflow to Benchmark the Clinical Cholestasis Risk of Drugs.
Vanessa Baier, Olivia Clayton, Ramona Nudischer, Henrik Cordes, Annika R P Schneider, Christoph Thiel, Timo Wittenberger, Wolfgang Moritz, Lars M Blank, Ulf P Neumann,[...]. Clin Pharmacol Ther 2021
Vanessa Baier, Olivia Clayton, Ramona Nudischer, Henrik Cordes, Annika R P Schneider, Christoph Thiel, Timo Wittenberger, Wolfgang Moritz, Lars M Blank, Ulf P Neumann,[...]. Clin Pharmacol Ther 2021
100
A Model-Based Approach to Assess Unstable Creatinine Clearance in Critically Ill Patients.
Sami Ullah, Michael Zoller, Ulrich Jaehde, Mikayil Huseyn-Zada, Thomas Weig, Uwe Fuhr, Usman Arshad, Johannes Zander, Max Taubert. Clin Pharmacol Ther 2021
Sami Ullah, Michael Zoller, Ulrich Jaehde, Mikayil Huseyn-Zada, Thomas Weig, Uwe Fuhr, Usman Arshad, Johannes Zander, Max Taubert. Clin Pharmacol Ther 2021
100
Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective.
Mohamad Shebley, Punam Sandhu, Arian Emami Riedmaier, Masoud Jamei, Rangaraj Narayanan, Aarti Patel, Sheila Annie Peters, Venkatesh Pilla Reddy, Ming Zheng, Loeckie de Zwart,[...]. Clin Pharmacol Ther 2018
Mohamad Shebley, Punam Sandhu, Arian Emami Riedmaier, Masoud Jamei, Rangaraj Narayanan, Aarti Patel, Sheila Annie Peters, Venkatesh Pilla Reddy, Ming Zheng, Loeckie de Zwart,[...]. Clin Pharmacol Ther 2018
16
Physiologically-Based Pharmacokinetic Modeling to Support the Clinical Management of Drug-Drug Interactions With Bictegravir.
Felix Stader, Manuel Battegay, Catia Marzolini. Clin Pharmacol Ther 2021
Felix Stader, Manuel Battegay, Catia Marzolini. Clin Pharmacol Ther 2021
25
The Complex Roadmap to Infectious Disease Innovation: The Intersection of Bugs, Drugs, and Special Populations.
Melanie R Nicol, Emily J Cicali, Shirley K Seo, Gauri G Rao. Clin Pharmacol Ther 2021
Melanie R Nicol, Emily J Cicali, Shirley K Seo, Gauri G Rao. Clin Pharmacol Ther 2021
50
Physiologically-Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug-Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations.
Kunal S Taskar, Venkatesh Pilla Reddy, Howard Burt, Maria M Posada, Manthena Varma, Ming Zheng, Mohammed Ullah, Arian Emami Riedmaier, Ken-Ichi Umehara, Jan Snoeys,[...]. Clin Pharmacol Ther 2020
Kunal S Taskar, Venkatesh Pilla Reddy, Howard Burt, Maria M Posada, Manthena Varma, Ming Zheng, Mohammed Ullah, Arian Emami Riedmaier, Ken-Ichi Umehara, Jan Snoeys,[...]. Clin Pharmacol Ther 2020
16
Drug-Drug Interactions Involving Renal OCT2/MATE Transporters: Clinical Risk Assessment May Require Endogenous Biomarker-Informed Approach.
Sumathy Mathialagan, Bo Feng, A David Rodrigues, Manthena V S Varma. Clin Pharmacol Ther 2021
Sumathy Mathialagan, Bo Feng, A David Rodrigues, Manthena V S Varma. Clin Pharmacol Ther 2021
16
Public Workshop Summary Report on Fiscal Year 2021 Generic Drug Regulatory Science Initiatives: Data Analysis and Model-Based Bioequivalence.
Jieon Lee, Yuqing Gong, Sid Bhoopathy, Charles E DiLiberti, Andrew C Hooker, Amin Rostami-Hodjegan, Stephan Schmidt, Sandra Suarez-Sharp, Viera Lukacova, Lanyan Fang,[...]. Clin Pharmacol Ther 2021
Jieon Lee, Yuqing Gong, Sid Bhoopathy, Charles E DiLiberti, Andrew C Hooker, Amin Rostami-Hodjegan, Stephan Schmidt, Sandra Suarez-Sharp, Viera Lukacova, Lanyan Fang,[...]. Clin Pharmacol Ther 2021
100
Precision Dosing: The Clinical Pharmacology of Goldilocks.
Richard W Peck, Mohamed H Shahin, Alexander A Vinks. Clin Pharmacol Ther 2021
Richard W Peck, Mohamed H Shahin, Alexander A Vinks. Clin Pharmacol Ther 2021
20
Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation.
S F Marshall, R Burghaus, V Cosson, S Y A Cheung, M Chenel, O DellaPasqua, N Frey, B Hamrén, L Harnisch, F Ivanow,[...]. CPT Pharmacometrics Syst Pharmacol 2016
S F Marshall, R Burghaus, V Cosson, S Y A Cheung, M Chenel, O DellaPasqua, N Frey, B Hamrén, L Harnisch, F Ivanow,[...]. CPT Pharmacometrics Syst Pharmacol 2016
16
Moving From Point-Based Analysis to Systems-Based Modeling: Integration of Knowledge to Address Antimicrobial Resistance Against MDR Bacteria.
Estefany Garcia, Neang Ly, John K Diep, Gauri G Rao. Clin Pharmacol Ther 2021
Estefany Garcia, Neang Ly, John K Diep, Gauri G Rao. Clin Pharmacol Ther 2021
16
A Drug-Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid, on Cytochrome P450 Activity in the Liver.
Daphne Vassiliou, Eliane Sardh, Pauline Harper, Amy R Simon, Valerie A Clausen, Nader Najafian, Gabriel J Robbie, Sagar Agarwal. Clin Pharmacol Ther 2021
Daphne Vassiliou, Eliane Sardh, Pauline Harper, Amy R Simon, Valerie A Clausen, Nader Najafian, Gabriel J Robbie, Sagar Agarwal. Clin Pharmacol Ther 2021
16
Exposure-Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma.
Geraldine Ferron-Brady, Chetan Rathi, Jon Collins, Herbert Struemper, Joanna Opalinska, Sandra Visser, Roxanne C Jewell. Clin Pharmacol Ther 2021
Geraldine Ferron-Brady, Chetan Rathi, Jon Collins, Herbert Struemper, Joanna Opalinska, Sandra Visser, Roxanne C Jewell. Clin Pharmacol Ther 2021
100
Quantitative Clinical Pharmacology Supports the Bridging From i.v. Dosing and Approval of s.c. Rituximab in B-Cell Hematological Malignancies.
Candice Jamois, Ekaterina Gibiansky, Leonid Gibiansky, Clarisse Chavanne, Peter N Morcos, Christine McIntyre, Martin Barrett, Linda Lundberg, Artem Zharkov, Axel Boehnke,[...]. Clin Pharmacol Ther 2021
Candice Jamois, Ekaterina Gibiansky, Leonid Gibiansky, Clarisse Chavanne, Peter N Morcos, Christine McIntyre, Martin Barrett, Linda Lundberg, Artem Zharkov, Axel Boehnke,[...]. Clin Pharmacol Ther 2021
100
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Michael Z Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N Liu, Chunze Li. Clin Pharmacol Ther 2021
Michael Z Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N Liu, Chunze Li. Clin Pharmacol Ther 2021
50
Clinical Design and Analysis Strategies for the Development of Gene Therapies: Considerations for Quantitative Drug Development in the Age of Genetic Medicine.
Avery McIntosh, Oleksandr Sverdlov, Li Yu, Petra Kaufmann. Clin Pharmacol Ther 2021
Avery McIntosh, Oleksandr Sverdlov, Li Yu, Petra Kaufmann. Clin Pharmacol Ther 2021
50
Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.
Kimberly L Johung, Norman Yeh, Neil B Desai, Terence M Williams, Tim Lautenschlaeger, Nils D Arvold, Matthew S Ning, Albert Attia, Christine M Lovly, Sarah Goldberg,[...]. J Clin Oncol 2016
Kimberly L Johung, Norman Yeh, Neil B Desai, Terence M Williams, Tim Lautenschlaeger, Nils D Arvold, Matthew S Ning, Albert Attia, Christine M Lovly, Sarah Goldberg,[...]. J Clin Oncol 2016
16
The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants.
Joseph Chen, Huiping Xu, Sylvester Pawlak, Leonard P James, Gerson Peltz, Kimberly Lee, Katherine Ginman, Michelle Bergeron, Yazdi K Pithavala. Adv Ther 2020
Joseph Chen, Huiping Xu, Sylvester Pawlak, Leonard P James, Gerson Peltz, Kimberly Lee, Katherine Ginman, Michelle Bergeron, Yazdi K Pithavala. Adv Ther 2020
16
Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.
Ted W Johnson, Paul F Richardson, Simon Bailey, Alexei Brooun, Benjamin J Burke, Michael R Collins, J Jean Cui, Judith G Deal, Ya-Li Deng, Dac Dinh,[...]. J Med Chem 2014
Ted W Johnson, Paul F Richardson, Simon Bailey, Alexei Brooun, Benjamin J Burke, Michael R Collins, J Jean Cui, Judith G Deal, Ya-Li Deng, Dac Dinh,[...]. J Med Chem 2014
16
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.
Helen Y Zou, Luc Friboulet, David P Kodack, Lars D Engstrom, Qiuhua Li, Melissa West, Ruth W Tang, Hui Wang, Konstantinos Tsaparikos, Jinwei Wang,[...]. Cancer Cell 2015
Helen Y Zou, Luc Friboulet, David P Kodack, Lars D Engstrom, Qiuhua Li, Melissa West, Ruth W Tang, Hui Wang, Konstantinos Tsaparikos, Jinwei Wang,[...]. Cancer Cell 2015
16
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
Benjamin J Solomon, Tony Mok, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari,[...]. N Engl J Med 2014
Benjamin J Solomon, Tony Mok, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari,[...]. N Engl J Med 2014
16
Targeting brain metastases in ALK-rearranged non-small-cell lung cancer.
Isabella Zhang, Nicholas G Zaorsky, Joshua D Palmer, Ranee Mehra, Bo Lu. Lancet Oncol 2015
Isabella Zhang, Nicholas G Zaorsky, Joshua D Palmer, Ranee Mehra, Bo Lu. Lancet Oncol 2015
16
Consensus Recommendations for Management and Counseling of Adverse Events Associated With Lorlatinib: A Guide for Healthcare Practitioners.
Mollie Reed, Aimee-Lauren S Rosales, Marc D Chioda, Lindsey Parker, Geeta Devgan, Jacob Kettle. Adv Ther 2020
Mollie Reed, Aimee-Lauren S Rosales, Marc D Chioda, Lindsey Parker, Geeta Devgan, Jacob Kettle. Adv Ther 2020
16
A user's guide to lorlatinib.
Misako Nagasaka, Yubin Ge, Ammar Sukari, Geetika Kukreja, Sai-Hong Ignatius Ou. Crit Rev Oncol Hematol 2020
Misako Nagasaka, Yubin Ge, Ammar Sukari, Geetika Kukreja, Sai-Hong Ignatius Ou. Crit Rev Oncol Hematol 2020
16
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.
Ryohei Katayama, Alice T Shaw, Tahsin M Khan, Mari Mino-Kenudson, Benjamin J Solomon, Balazs Halmos, Nicholas A Jessop, John C Wain, Alan Tien Yeo, Cyril Benes,[...]. Sci Transl Med 2012
Ryohei Katayama, Alice T Shaw, Tahsin M Khan, Mari Mino-Kenudson, Benjamin J Solomon, Balazs Halmos, Nicholas A Jessop, John C Wain, Alan Tien Yeo, Cyril Benes,[...]. Sci Transl Med 2012
16
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.
Justin F Gainor, Leila Dardaei, Satoshi Yoda, Luc Friboulet, Ignaty Leshchiner, Ryohei Katayama, Ibiayi Dagogo-Jack, Shirish Gadgeel, Katherine Schultz, Manrose Singh,[...]. Cancer Discov 2016
Justin F Gainor, Leila Dardaei, Satoshi Yoda, Luc Friboulet, Ignaty Leshchiner, Ryohei Katayama, Ibiayi Dagogo-Jack, Shirish Gadgeel, Katherine Schultz, Manrose Singh,[...]. Cancer Discov 2016
16
Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
Gouji Toyokawa, Takashi Seto, Mitsuhiro Takenoyama, Yukito Ichinose. Cancer Metastasis Rev 2015
Gouji Toyokawa, Takashi Seto, Mitsuhiro Takenoyama, Yukito Ichinose. Cancer Metastasis Rev 2015
16
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
D Ross Camidge, Rafal Dziadziuszko, Solange Peters, Tony Mok, Johannes Noe, Malgorzata Nowicka, Shirish M Gadgeel, Parneet Cheema, Nick Pavlakis, Filippo de Marinis,[...]. J Thorac Oncol 2019
D Ross Camidge, Rafal Dziadziuszko, Solange Peters, Tony Mok, Johannes Noe, Malgorzata Nowicka, Shirish M Gadgeel, Parneet Cheema, Nick Pavlakis, Filippo de Marinis,[...]. J Thorac Oncol 2019
16
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.
Neal I Lindeman, Philip T Cagle, Dara L Aisner, Maria E Arcila, Mary Beth Beasley, Eric H Bernicker, Carol Colasacco, Sanja Dacic, Fred R Hirsch, Keith Kerr,[...]. Arch Pathol Lab Med 2018
Neal I Lindeman, Philip T Cagle, Dara L Aisner, Maria E Arcila, Mary Beth Beasley, Eric H Bernicker, Carol Colasacco, Sanja Dacic, Fred R Hirsch, Keith Kerr,[...]. Arch Pathol Lab Med 2018
16
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.